Scientists have found a way to transform hard-to-treat tumors into targets for the immune system. Using two protein stimulators, they activated strong T-cell and B-cell responses and built immune ...

MRT-6160 inhibited disease pathology, including proteinuria, lymphadenopathy, skin lesion formation, autoantibody production, and organomegaly, ...

Germinal center B-cell–like diffuse large B-cell lymphomas (GCB-DLBCLs) show dependence on DOT1L and EZH2, with combined targeting offering potential as an alternative differentiation-based therapy.

Blood cancers such as leukemia, lymphoma, and myeloma often begin in the bone marrow and disrupt normal blood cell formation.

A research team at The University of Osaka, joined by Professor Shimon Sakaguchi—the latest Nobel Laureate in Physiology or Medicine—has identified a previously uncharacterized subset of immune cells ...